MX2018001802A - Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino. - Google Patents

Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino.

Info

Publication number
MX2018001802A
MX2018001802A MX2018001802A MX2018001802A MX2018001802A MX 2018001802 A MX2018001802 A MX 2018001802A MX 2018001802 A MX2018001802 A MX 2018001802A MX 2018001802 A MX2018001802 A MX 2018001802A MX 2018001802 A MX2018001802 A MX 2018001802A
Authority
MX
Mexico
Prior art keywords
oxaliplatin
liposomal irinotecan
pancreatic cancer
methods
combination therapies
Prior art date
Application number
MX2018001802A
Other languages
English (en)
Inventor
Basil Fitzgerald Jonathan
Bayever Eliel
S Hendriks Bart
F Blanchette Sarah
F Gaddy Daniel
Kalra Ashish
Lee Helen
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100730&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018001802(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of MX2018001802A publication Critical patent/MX2018001802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los regímenes de terapia de combinación que incluyen irinotecán liposomal, oxaliplatino y 5-fluorouracilo son útiles en el tratamiento del cáncer de páncreas, que incluye el tratamiento de pacientes diagnosticados con adenocarcinoma de páncreas metastásico no tratado previamente. La terapia de combinación puede incluir la administración de irinotecán liposomal, oxaliplatino, leucovorina y 5-fluorouracilo una vez cada dos semanas.
MX2018001802A 2015-08-21 2016-08-19 Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino. MX2018001802A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562208209P 2015-08-21 2015-08-21
US201562216736P 2015-09-10 2015-09-10
US201562273244P 2015-12-30 2015-12-30
US201662281473P 2016-01-21 2016-01-21
US201662302341P 2016-03-02 2016-03-02
US201662323245P 2016-04-15 2016-04-15
US201662343313P 2016-05-31 2016-05-31
PCT/US2016/047727 WO2017034957A1 (en) 2015-08-21 2016-08-19 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

Publications (1)

Publication Number Publication Date
MX2018001802A true MX2018001802A (es) 2018-05-16

Family

ID=58100730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001802A MX2018001802A (es) 2015-08-21 2016-08-19 Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino.

Country Status (18)

Country Link
US (3) US20170049775A1 (es)
EP (2) EP3791876A1 (es)
JP (3) JP2018528185A (es)
KR (1) KR20180039087A (es)
CN (1) CN108495629A (es)
AU (1) AU2016310476B8 (es)
BR (1) BR112018002941B1 (es)
CA (1) CA2993451A1 (es)
ES (1) ES2826826T3 (es)
HK (2) HK1257220A1 (es)
IL (1) IL257149B1 (es)
MX (1) MX2018001802A (es)
PT (1) PT3337478T (es)
RU (1) RU2747124C2 (es)
SG (1) SG10201913077QA (es)
SI (1) SI3337478T1 (es)
TW (4) TW202400181A (es)
WO (1) WO2017034957A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2015360761B2 (en) * 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
SG11201903615WA (en) 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
IL308722A (en) * 2018-10-17 2024-01-01 Biolinerx Ltd Treatment of metastatic adenocarcinoma of the pancreas
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020170164A1 (en) 2019-02-22 2020-08-27 Moshe Giladi Treating gastric cancer using ttfields combined with xelox or folfox
US20220378936A1 (en) * 2019-10-10 2022-12-01 The University Of North Carolina At Chapel Hill Delivery system complexes comprising a precipitate of an active agent and methods of use
WO2022266357A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napox
WO2022266354A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napoli

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
EP0949906A4 (en) 1996-10-22 2004-11-24 Hermes Biosciences Inc LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
DK1121102T3 (da) 1998-09-16 2003-08-11 Alza Corp Liposomindesluttede topoisomeraseinhibitorer
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
EP1259225B1 (en) 2000-02-04 2006-10-04 Lipoxen Technologies Limited Process of dehydration/rehydration for making liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
ATE322265T1 (de) 2000-05-15 2006-04-15 Celgene Corp Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
MXPA02012817A (es) 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
MXPA03008864A (es) 2001-03-26 2004-12-06 Johnson & Johnson Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico.
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
AU2002328953A1 (en) 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Use of irinotecan for improved treatment of cancer based on mdr1
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
WO2003101475A1 (en) 2002-05-31 2003-12-11 Transmolecular Inc. Treatment of cell proliferative disorders with chlorotoxin
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
KR20180014881A (ko) 2003-05-30 2018-02-09 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
PL1746976T3 (pl) 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
BRPI0511753A (pt) 2004-06-01 2008-01-02 Terumo Corp formulação de irinotecano e respectiva composição farmacêutica
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2006306108B2 (en) 2005-10-25 2012-10-04 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
ES2437132T3 (es) 2006-01-17 2014-01-09 Abbvie Bahamas Ltd. Tratamiento combinado con inhibidores de PARP
CA2647297A1 (en) 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
PT2716301T (pt) 2007-02-16 2017-07-04 Merrimack Pharmaceuticals Inc Anticorpos contra erbb3 e suas utilizações
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
JP2010540498A (ja) 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
MX2010005221A (es) 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
WO2009073869A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
JP2011515478A (ja) 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010125462A2 (en) 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
EP2508170B1 (en) 2009-12-03 2015-07-29 Jiangsu Hengrui Medicine Co., Ltd. Liposome of irinotecan or its hydrochloride and preparation method thereof
CN103140225A (zh) 2010-06-04 2013-06-05 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
JP2013531068A (ja) 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
US9220772B2 (en) 2010-07-22 2015-12-29 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
JP6208582B2 (ja) 2010-12-06 2017-10-04 メリマック ファーマシューティカルズ インコーポレーティッド アントラサイクリン系化学療法剤を含有しているｅｒｂｂ２標的免疫リポソームによる治療における心臓毒性を抑制するための用量及び投与
CA2821024A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
WO2012112730A2 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
JP5588086B2 (ja) 2011-04-19 2014-09-10 メリマック ファーマシューティカルズ インコーポレーティッド 単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
WO2013158803A1 (en) 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
RS58067B1 (sr) 2013-03-27 2019-02-28 Taiho Pharmaceutical Co Ltd Antitumorski agens koji uključuje irinotekan hidrohlorid hidrat u niskoj dozi
WO2015031536A1 (en) 2013-08-27 2015-03-05 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
US20160303264A1 (en) 2013-10-23 2016-10-20 Merrimack Pharmaceuticals, Inc. Liposomes useful for non-invasive imaging and drug delivery
AU2015360761B2 (en) 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
KR20190009319A (ko) 2016-05-18 2019-01-28 입센 바이오팜 리미티드 소세포 폐암을 치료하는데 사용하기 위한 나노리포솜성 이리노테칸
CN106420789A (zh) * 2016-10-08 2017-02-22 中国人民解放军总医院 复发耐药消化道肿瘤地西他滨综合治疗方案
SG11201903615WA (en) 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Also Published As

Publication number Publication date
AU2016310476A1 (en) 2018-02-22
CA2993451A1 (en) 2017-03-02
RU2018105666A3 (es) 2020-02-21
RU2747124C2 (ru) 2021-04-28
BR112018002941A2 (pt) 2018-11-27
SG10201913077QA (en) 2020-02-27
HK1257250A1 (zh) 2019-10-18
US20230062425A1 (en) 2023-03-02
TW202400181A (zh) 2024-01-01
AU2016310476B2 (en) 2021-09-30
JP2018528185A (ja) 2018-09-27
EP3791876A1 (en) 2021-03-17
US11344552B2 (en) 2022-05-31
EP3337478A1 (en) 2018-06-27
CN108495629A (zh) 2018-09-04
TW201717933A (zh) 2017-06-01
IL257149B1 (en) 2024-07-01
AU2016310476B8 (en) 2021-10-07
EP3337478B1 (en) 2020-08-12
BR112018002941B1 (pt) 2023-12-05
JP2024045587A (ja) 2024-04-02
TW202243677A (zh) 2022-11-16
WO2017034957A1 (en) 2017-03-02
KR20180039087A (ko) 2018-04-17
US20180078556A1 (en) 2018-03-22
SI3337478T1 (sl) 2020-10-30
TWI778942B (zh) 2022-10-01
JP7463329B2 (ja) 2024-04-08
HK1257220A1 (zh) 2019-10-18
PT3337478T (pt) 2020-10-19
IL257149A (en) 2018-03-29
RU2018105666A (ru) 2019-09-23
TW202126293A (zh) 2021-07-16
JP2022009657A (ja) 2022-01-14
ES2826826T3 (es) 2021-05-19
US20170049775A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
MX2018001802A (es) Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino.
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
PH12017550063A1 (en) Combination therapies for treating cancers
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2017007321A (es) Terapias de combinacion.
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MA40364A (fr) Polythérapie pour le traitement du cancer
MY176219A (en) Combination therapy for cancer
PH12016501407A1 (en) Treatment of neoplasia
MX2017015532A (es) Terapia de combinacion pac-1.
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).
MX2015015601A (es) Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1).
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
MX2021000110A (es) Terapia de combinacion con inhibicion dirigida de factor de crecimiento transformante beta (tgf-beta) para el tratamiento de cancer de pulmon avanzado de celulas no peque?as.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.